{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/insomnia/prescribing-information/z-drugs/","result":{"pageContext":{"chapter":{"id":"34ae23e7-59a3-54c1-80f6-944b0b43d4c4","slug":"z-drugs","fullItemName":"Z-drugs","depth":2,"htmlHeader":"<!-- begin field 2e4d7eed-6793-485c-977e-b4c6df67e396 --><h2>What issues should I be aware of when prescribing Z-drugs?</h2><!-- end field 2e4d7eed-6793-485c-977e-b4c6df67e396 -->","summary":"","htmlStringContent":"<!-- begin item 3820848b-0290-4f6a-8f4d-f14af9372bad --><!-- begin field c736f8f5-f02d-4c13-8f1d-c035e60f044f --><p>The National Institute for Health and Care Excellence (NICE) technology appraisal [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019a</a>] advises that hypnotics should be prescribed for short-term (up to two weeks) use <em>only </em>when non-drug measures have failed and insomnia is severe, disabling or causing extreme distress.</p><ul><li>The many risks associated with hypnotics such as falls, cognitive impairment, dependence and withdrawal symptoms, are well recognised [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Riemann, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019a</a>]. </li><li>The lowest dose that controls symptoms for the shortest period of time should be used [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019a</a>]. </li></ul><h3>Z-drugs licensed for the short-term management of insomnia include:</h3><ul><li>Zopiclone.<ul><li>In adults — 7.5 mg once daily at bedtime.</li><li>In the elderly (avoid if possible due to increased risk of adverse effects) — if essential reduce dose; initially 3.75 mg once daily at bedtime.</li><li>DO NOT re-administer during the same night.</li></ul></li><li>Zolpidem.<ul><li>In adults — 10 mg once daily at bedtime; for debilitated patients, use elderly dose.</li><li>In the elderly (avoid if possible due to increased risk of adverse effects) — if essential reduce dose; 5 mg maximum once daily at bedtime.</li><li>DO NOT re-administer during the same night.</li></ul></li></ul><h3>Contraindications and cautions</h3><ul><li>Z-drugs are contraindicated in:<ul><li>Marked neuromuscular respiratory weakness.</li><li>Respiratory failure.</li><li>Myasthenia gravis.</li><li>Obstructive sleep apnoea.</li><li>Pregnancy and breastfeeding — risk of neonatal respiratory depression and withdrawal symptoms.</li><li>Severe hepatic impairment.</li><li>Psychotic illness.</li></ul></li></ul><ul><li>Z-drugs should be prescribed with caution in:<ul><li>Chronic pulmonary insufficiency — increased risk of respiratory depression.</li><li>The elderly — avoid if possible due to increased risk of adverse effects including falls and fractures.</li><li>History of drug or alcohol abuse — manufacturer recommends extreme caution.</li><li>Muscle weakness.</li><li>Psychiatric illness including depression.</li><li>Hepatic and renal impairment — reduce dose, avoid if severe.</li></ul></li></ul><h3>Adverse effects</h3><ul><li>The adverse effects of Z-drugs include:<ul><li>Gastrointestinal effects such as dry mouth, abdominal pain, nausea, vomiting and diarrhoea.</li><li>Psychiatric effects such as anterograde amnesia, impaired cognition and concentration, depression, suicidal ideation and attempt, anxiety, psychosis and behavioural abnormalities, restlessness, agitation, irritability, aggression, delusions, anger, nightmares, hallucinations, and inappropriate behaviour.</li><li>Neurological effects such as confusion, dizziness, hallucination, headache, sleep disorders, ataxia, falls, muscle weakness, respiratory depression and decreased level of consciousness.</li></ul></li><li>Drowsiness may persist the following day and affect performance of skilled tasks such as driving.<ul><li>The Medicines and Healthcare Products Regulatory Agency (MHRA) advises that people who take zolpidem should:<ul><li>Only take 10 mg of zolpidem at bedtime and not take it again the same night (people with liver impairment and the elderly should take no more than 5 mg of zolpidem a night).</li><li>Not drive, operate machinery, or work at heights until at least 8 hours after taking zolpidem.</li><li>Not take zolpidem with alcohol, illicit drugs, or other central nervous system suppressants.</li></ul></li><li>A new offence of driving with controlled drugs (including opioids and some hypnotics) above specified limits in the blood, came into force in March 2015. Further information ‘Drugs and driving: the law’ is available at <a href=\"http://www.gov.uk/\" data-hyperlink-id=\"afad5e5c-0a5b-48cb-a5b9-ab5100a4989c\">www.gov.uk</a>.</li><li>The manufacturer advises that the risk of psychomotor impairment (including impaired driving ability) is increased if:<ul><li>Zopiclone is taken within 12 hours of performing activities requiring mental alertness.</li><li>A dose higher than the recommended dose is taken.</li><li>Zopiclone is co-administered with alcohol, other CNS depressants or drugs that increase the blood levels of zopiclone.</li></ul></li><li>Studies have shown that women tend to have higher blood concentrations of zolpidem and greater impairment of driving ability the following morning than men — the US Food and Drugs Administration recommend dosing for women at half that for men.</li></ul></li><li>Tolerance, dependence and withdrawal syndrome may develop.<ul><li>For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/benzodiazepine-z-drug-withdrawal/\">Benzodiazepine and z-drug withdrawal</a>. </li></ul></li></ul><h3>Drug interactions</h3><ul><li><strong>Drug interactions of Z-drugs include</strong>:<ul><li>Alcohol and opioids — avoid concomitant use as this can:<ul><li>Induce sedation, respiratory depression, coma, and death by potentiating effects of hypnotics.</li><li>Affect ability to perform skilled tasks.</li></ul></li><li>Centrally acting drugs — possible enhanced central depressive effect if co-administered with centrally acting drugs such as neuroleptics, antipsychotics, antidepressants, anaesthetics and sedative antihistamines.</li><li>Drugs that inhibit cytochrome P450 enzyme (for example ciprofloxacin, azole antifungals, and oestrogens).<ul><li>Avoid concomitant use — can result in increased serum levels of Z-drugs leading to increased effect.</li></ul></li><li>Drugs that induce cytochrome P450 enzyme (for example St John's Wort and rifampicin).<ul><li>Cytochrome P450 inducers can accelerate hepatic elimination of Z-drugs and decrease their action.</li></ul></li><li>Phenytoin — concomitant use may increase or decrease serum concentrations of phenytoin; monitor phenytoin concentrations.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">MHRA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Qaseem, 2016</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">ABPI, 2019c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">BNF, 2019</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Wilson, 2019</a>]</p><!-- end field c736f8f5-f02d-4c13-8f1d-c035e60f044f --><!-- end item 3820848b-0290-4f6a-8f4d-f14af9372bad -->","topic":{"id":"d32ed400-7d0f-58c1-b35a-07cabeb7198f","topicId":"c95c9c90-991c-42bf-9bb6-260f08eb9d32","topicName":"Insomnia","slug":"insomnia","lastRevised":"Last revised in January 2020","chapters":[{"id":"99b2443e-da9c-5c9d-8066-cea961d77010","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"775bdb91-759e-5182-aa24-3faa2be61175","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4b1bac5b-de37-521d-afa3-7222f1f8a344","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"079ebee9-04a4-5115-ad9d-4ec64285cafe","slug":"changes","fullItemName":"Changes"},{"id":"fadd9470-736e-56b5-9e47-fabc4c25c40a","slug":"update","fullItemName":"Update"}]},{"id":"6d4dc1da-3cad-586f-9720-807538e37ae0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"dd70908f-732c-56f4-96ee-63c1a0d48b93","slug":"goals","fullItemName":"Goals"},{"id":"7c916994-5730-5df1-a42d-0903da669227","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3babc745-3146-54d7-a591-229458269920","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c9a1ae6b-b43f-5001-9ce6-eec4fe6a51d6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"782e1bf0-98b1-5461-be78-dcabc4e8768b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bf1c4d94-7a24-5b6b-b08e-2e91d584da67","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f99b4301-f0d0-5b2d-9c5d-5448b2c5ae71","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e829a9d8-9a8a-5fff-acc0-b36a76b06365","slug":"definition","fullItemName":"Definition"},{"id":"71bd7cfa-09cb-59bc-8596-cf8b380bdfc8","slug":"causes","fullItemName":"Causes"},{"id":"d3f6ead4-def6-5d80-82da-6a216bbf5205","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a96dbcb1-2be5-5896-958a-015d9d9ff705","slug":"prognosis","fullItemName":"Prognosis"},{"id":"d70599ab-d67b-56eb-a550-5eb50783af51","slug":"complications","fullItemName":"Complications"}]},{"id":"908b4222-ad0d-5cb4-b245-b6613b9935af","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1ef90db4-827f-5f00-89c3-71b0b81deeed","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"db78ccd5-ae24-5f11-9afb-47d56a4e8c1a","slug":"assessment","fullItemName":"Assessment"},{"id":"e1f82dba-1dd1-5cd6-89fd-df0bb7eea4b2","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0b989149-2d7c-55da-a785-3b93e4e9e30d","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d6f6f9c-bb55-5871-81f4-30b4b0e1e3ce","slug":"managing-short-term-insomnia-less-3-months","fullItemName":"Scenario: Managing short-term insomnia (< 3 months)"},{"id":"9c9c0f54-a495-58d5-9a6f-00b3ea587356","slug":"managing-long-term-insomnia-greater-3-months","fullItemName":"Scenario: Managing long-term insomnia (> 3 months)"}]},{"id":"d5ba983f-3e5f-57df-9f8b-dcf81a11b4e9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"34ae23e7-59a3-54c1-80f6-944b0b43d4c4","slug":"z-drugs","fullItemName":"Z-drugs"},{"id":"c581c21d-a147-50d8-8437-df289bb720bf","slug":"melatonin","fullItemName":"Melatonin"}]},{"id":"787787e5-4b3f-5665-bb53-35fba2334669","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"248c0d90-0e6b-5fc7-b6ab-94f0aca25c78","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"964993b0-a6a2-584e-b2b2-1d307e45d4a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4fc22a18-8f09-58a9-aaf9-e4d181a88b4b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3eed36c6-8b0c-5776-aa33-aba8181960d9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e9c29199-597b-5045-bb8e-91f46f5641cc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"54861215-5c9f-5992-83e2-44e0d123cd39","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"40987924-ac87-5c7f-8d13-d6233cd2729a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d5ba983f-3e5f-57df-9f8b-dcf81a11b4e9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}